Moore M M
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021.
Semin Surg Oncol. 1991 Sep-Oct;7(5):267-70. doi: 10.1002/ssu.2980070507.
Ductal carcinoma in situ (DCIS) is increasing in frequency, primarily because of the increasing use of routine screening mammography. The management of DCIS has become one of the more controversial aspects in the treatment of breast cancer. Although total mastectomy provides local control and long-term survival approaching 100%, the move to breast conservation with early invasive breast cancer has forced a re-evaluation of the treatment of in situ breast cancer. Recent advances in the evaluation and subclassification of DCIS according to histologic subgroupings and sizings have provided valuable insight into the biology of the disease. These biologic parameters may help to identify those lesions amenable to breast conservation. In properly selected patients, breast conservation affords a 1%/year local failure rate, with approximately one-half of the recurrences being invasive.
导管原位癌（DCIS）的发病率正在上升，主要原因是常规乳腺钼靶筛查的使用增加。DCIS的治疗已成为乳腺癌治疗中争议较大的方面之一。尽管全乳切除术能提供局部控制，长期生存率接近100%，但随着早期浸润性乳腺癌保乳治疗的开展，促使人们重新评估原位乳腺癌的治疗。根据组织学亚组和大小对DCIS进行评估和亚分类的最新进展，为了解该疾病的生物学特性提供了有价值的见解。这些生物学参数可能有助于识别适合保乳治疗的病变。在经过适当选择的患者中，保乳治疗的局部失败率为每年1%，其中约一半的复发为浸润性。
